
MiMedx Group (MDXG) Stock Forecast & Price Target
MiMedx Group (MDXG) Analyst Ratings
Bulls say
MiMedx Group Inc has demonstrated robust financial performance, achieving a 13% year-over-year revenue growth, with total revenues reported at $98.6 million driven significantly by both the wound care and surgical segments. The wound portfolio increased by 12% to $64.5 million, while the surgical business saw a 15% increase to $34.1 million, indicating strong demand and market positioning in its targeted sectors. Additionally, the company's upward revision of its 2025 revenue estimate to $387.3 million reflects positive momentum, backed by strong performance in the second quarter of 2025.
Bears say
MiMedx Group Inc. has experienced a decline in gross margin, decreasing to approximately 81% from 83% in the second quarter of 2025, primarily due to production variances and product mix, which may indicate underlying operational inefficiencies. Although the company aims for low double-digit year-over-year revenue growth and an adjusted EBITDA margin exceeding 20% in the long term, the pressure on margins raises concerns about its ability to achieve such targets consistently. Furthermore, potential adverse changes in reimbursement rates from CMS could significantly impact the company’s revenue trajectory, adding additional risks to its financial outlook.
This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.
MiMedx Group (MDXG) Analyst Forecast & Price Prediction
Start investing in MiMedx Group (MDXG)
Order type
Buy in
Order amount
Est. shares
0 shares